Pfizer Inc. and BioNTech SE are on the track to develop Covid-19 vaccine. In the phase of trial, the vaccines developed by the duo prevented more than 90% of infection. This statement is supported by a study that says more than ten of thousands of volunteers were tested by the vaccine. It is eight-month and counting that the pandemic has shown its curse on the world. And this first preliminary result has paved a way for the companies to use it only if the shot is safe.
The research said that it is an interim analysis conducted on 94 participants who were contracted by Covid-19 vaccine. The same trial will continue for a while until there are 164 cases. If the data and the research hold up best Pfizer expects to reach out the vaccine in about a week and this could mean that the world will have a vital new tool to regulate the pandemic that has killed around 1.2 million people worldwide and counting.
Quote By Pfizer and BioNTech : Covid-19 vaccine
In this concern, Pfizer’s senior vice president for vaccine clinical research and development William Gruber said, “This is about the best the news could possibly be for the world and for the United States and for public health”. The senior vice president of Pfizer also said that it was better than even the best result he had hoped.
BioNTech Chief Executive Officer Ugur Sahin also said, “With effectiveness for the first vaccines previously expected to be in the range of 60% to 70%, “more than 90% is extraordinary,” Sahin in an interview said that is the ‘Victory of Science’ as the research shows that Covid-19 can be controlled”
Pfizer is expecting to get two months of safety follow-up data of the vaccine. It is a key metric that is required by U.S. regulators before they provide emergency authorization. If everything goes well, the emergency authorization would be granted, in the third week in November. However, if those finding does not raise any problem, Pfizer would apply for authorization in the U.S. this month.
Running Ahead in the Race
It is the positive preliminary data of both U.S. pharma giant and the German partner is on the right track. They can be to be first to bring up the vaccine after signing the advance deals with governments worldwide. The companies said they should be able to produce around 1.3 billion doses. This seems to be enough to vaccinate 650 million people by the end of 2021. The report also says that only 50 million doses will be available for the year 2020.